Recent Updates
Recently added Catalysts
JNJ Positive Sentiment

Riassunto: Johnson & Johnson riceve il marchio CE per le lenti a contatto riutilizzabili ACUVUE OASYS MAX

Thursday, September 10, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Johnson & Johnson has announced the receipt of the CE mark for its new ACUVUE OASYS MAX 2-Week reusable contact lenses. These lenses utilize proprietary MAX technologies to provide superior comfort and maintain clear vision even after 14 days of use. This approval marks a significant advancement in their product offerings.

Market Sentiment Analysis

POSITIVE FACTORS

  • Johnson & Johnson received CE mark for new product.
  • ACUVUE OASYS MAX lenses offer superior comfort.
  • Lenses maintain clear vision for up to 14 days.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+34%
120-day peak, hindsight
Typical move
1.6%
average across 15 past catalysts
Lead asset
Canagliflozin
Phase 3 · Diabetes Mellitus, Type 2

Full Press Release Details

LIMERICK, Irlanda--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) oggi ha annunciato di aver ricevuto il marchio CE per ACUVUE OASYS MAX 2-Week,*** una nuova lente a contatto riutilizzabile basata su tecnologie proprietarie MAX progettate per garantire un comfort superiore e visione nitida anche 14 giorni dopo il primo utilizzo. Il testo originale del presente annuncio, redatto nella lingua di partenza, è la versione ufficiale che fa fede. Le traduzioni sono offerte unicamente per comodità

Frequently Asked Questions

What is the ACUVUE OASYS MAX?

The ACUVUE OASYS MAX is a new reusable contact lens by Johnson & Johnson.

How long can the ACUVUE OASYS MAX lenses be used?

These lenses can be used for up to 14 days after the first use.

What technology do ACUVUE OASYS MAX lenses use?

They are based on proprietary MAX technologies for superior comfort.

What certification did Johnson & Johnson receive?

They received the CE mark for the ACUVUE OASYS MAX lenses.

ShareAdd on Google
Tags: JNJ Viatris Investor Conferences Healthcare Johnson & Johnson ACUVUE OASYS MAX CE mark contact lenses reusable lenses
Last updated: Sep 10, 2026

Biotech snapshot

Cash runway
$20758M liquidity · $0M/mo burn
Low dilution risk
Lead asset
CanagliflozinPhase 3
Diabetes Mellitus, Type 2 →

Catalyst track record

+34%
best trade around JNJ's most recent catalyst

Peak hindsight return over a 120-day window, across 15 tracked FDA/PDUFA catalysts for JNJ.

See every catalyst's timing & PoA →